Clinical course of oxaliplatin-induced neuropathy: Results from the randomized phase III trial N08CB (Alliance)

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3416-3422

  Pachman, Deirdre R ^a   Qin, Rui ^a   Seisler, Drew K ^a   Smith, Ellen M L ^b   Beutler, Andreas S ^a   Ta, Lauren E ^a   Lafky, Jacqueline M ^a   Wagner Johnston, Nina D ^c   Ruddy, Kathryn J ^a   Dakhil, Shaker ^d   Staff, Nathan P ^a   Grothey, Axel ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Cancer Center of Kansas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FLUOROURACIL; FOLINIC ACID; MAGNESIUM; OXALIPLATIN; ANTINEOPLASTIC AGENT; CALCIUM DERIVATIVE; MAGNESIUM DERIVATIVE; PLATINUM COMPLEX;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; COLON CANCER; DISEASE COURSE; DYSPHAGIA; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TINGLING; TEMPERATURE SENSITIVITY; THROAT DISEASE; ACUTE DISEASE; CHEMICALLY INDUCED; CHRONIC DISEASE; CLINICAL TRIAL; COLONIC NEOPLASMS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; NEUROTOXICITY SYNDROMES; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM COMPOUNDS; CHRONIC DISEASE; COLONIC NEOPLASMS; DOUBLE-BLIND METHOD; FLUOROURACIL; HUMANS; LEUCOVORIN; MAGNESIUM COMPOUNDS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84944463352     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.8533     Document Type: Article

References (28)

1. Kidwell KM, Yothers G, Ganz PA, et al: Longterm neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 118:5614-5622, 2012
2. Mols F, Beijers T, Lemmens V, et al: Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. J Clin Oncol 31:2699-2707, 2013
3. Pietrangeli A, Leandri M, Terzoli E, et al: Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56:13-16, 2006
4. Tofthagen C, Donovan KA, Morgan MA, et al: Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. Supp Care Cancer 21:3307-3313, 2013
5. Argyriou AA, Cavaletti G, Briani C, et al: Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer. Cancer 119:438-444, 2013
6. Park SB, Goldstein D, Lin CS, et al: Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27:1243-1249, 2009
7. Velasco R, Bruna J, Briani C, et al: Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85:392-398, 2014
8. Loprinzi CL, et al: Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity, (N08CB/Alliance). J Clin Oncol 32:997-1005, 2014
9. de Boer AG, van Lanschot JJ, Stalmeier PF, et al: Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res 13:311-320, 2004
10. Hauser K, Walsh D: Visual analogue scales and assessment of quality of life in cancer. J Support Oncol 6:277-282, 2008
11. Kindler CH, Harms C, Amsler F, et al: The visual analog scale allows effective measurement of preoperative anxiety and detection of patients' anesthetic concerns. Anesth Analg 90:706-712, 2000
12. Locke DE, Decker PA, Sloan JA, et al: Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage 34:628-638, 2007
13. Lavoie Smith EM, Barton DL, Qin R, et al: Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-2799, 2013
14. Postma TJ, Aaronson NK, Heimans JJ, et al: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 41:1135-1139, 2005
15. Lehky TJ, Leonard GD, Wilson RH, et al: Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle Nerve 29: 387-392, 2004
16. Ta LE, Low PA, Windebank AJ: Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Molecular Pain 5:9 2009
17. Land SR, Kopec JA, Cecchini RS, et al: Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205-2211, 2007
18. Leonard GD, Wright MA, Quinn MG, et al: Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116 2005
19. Tofthagen C, McAllister RD, McMillan SC: Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs 15: 182-188, 2011
20. Wolf SL, Barton DL, Qin R, et al: The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Supp Care Cancer 20:625-632, 2012
21. Grunberg SM, Sonka S, Stevenson LL, et al: Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 25:62-64, 1989
22. LoMonaco M, Milone M, Batocchi AP, et al: Cisplatin neuropathy: Clinical course and neurophysiological findings. J Neurol 239:199-204, 1992
23. Podratz JL, Knight AM, Ta LE, et al: Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 41:661-668, 2011
24. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17, 2002
25. Choi J, Kong K, Mozaffar T, et al: Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 17:103-105, 2006
26. Alejandro LM, Behrendt CE, Chen K, et al: Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 36:331-337, 2013
27. Loprinzi CL, Reeves BN, Dakhil SR, et al: Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472-1478, 2011
28. Reeves BN, Dakhil SR, Sloan JA, et al: Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171-5178, 2012